239 related articles for article (PubMed ID: 32410138)
1. 5-Azacytidine upregulates melatonin MT
Hartung EE; Mukhtar SZ; Shah SM; Niles LP
Mol Biol Rep; 2020 Jun; 47(6):4867-4873. PubMed ID: 32410138
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic induction of melatonin MT
Bahna SG; Niles LP
Eur Neuropsychopharmacol; 2017 Aug; 27(8):828-832. PubMed ID: 28648552
[TBL] [Abstract][Full Text] [Related]
3. Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells.
Kim B; Rincón Castro LM; Jawed S; Niles LP
Eur J Pharmacol; 2008 Jul; 589(1-3):45-8. PubMed ID: 18550052
[TBL] [Abstract][Full Text] [Related]
4. Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells.
Castro LM; Gallant M; Niles LP
J Neurochem; 2005 Dec; 95(5):1227-36. PubMed ID: 16313512
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation of melatonin receptors in neuropsychiatric disorders.
Bahna SG; Niles LP
Br J Pharmacol; 2018 Aug; 175(16):3209-3219. PubMed ID: 28967098
[TBL] [Abstract][Full Text] [Related]
6. Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation.
Jawed S; Kim B; Ottenhof T; Brown GM; Werstiuk ES; Niles LP
Eur J Pharmacol; 2007 Mar; 560(1):17-22. PubMed ID: 17303109
[TBL] [Abstract][Full Text] [Related]
7. Regional upregulation of hippocampal melatonin MT2 receptors by valproic acid: therapeutic implications for Alzheimer's disease.
Bahna SG; Sathiyapalan A; Foster JA; Niles LP
Neurosci Lett; 2014 Jul; 576():84-7. PubMed ID: 24909617
[TBL] [Abstract][Full Text] [Related]
8. Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers.
Niles LP; Armstrong KJ; Rincón Castro LM; Dao CV; Sharma R; McMillan CR; Doering LC; Kirkham DL
BMC Neurosci; 2004 Oct; 5():41. PubMed ID: 15511288
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic targets for melatonin: induction of histone H3 hyperacetylation and gene expression in C17.2 neural stem cells.
Sharma R; Ottenhof T; Rzeczkowska PA; Niles LP
J Pineal Res; 2008 Oct; 45(3):277-84. PubMed ID: 18373554
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid up-regulates melatonin MT1 and MT2 receptors and neurotrophic factors CDNF and MANF in the rat brain.
Niles LP; Sathiyapalan A; Bahna S; Kang NH; Pan Y
Int J Neuropsychopharmacol; 2012 Oct; 15(9):1343-50. PubMed ID: 22243807
[TBL] [Abstract][Full Text] [Related]
11. Gender-related invasion differences associated with mRNA expression levels of melatonin membrane receptors in colorectal cancer.
León J; Casado J; Carazo A; Sanjuán L; Maté A; Muñoz de Rueda P; de la Cueva P; Quiles R; Ruíz S; Ruíz-Extremera A; Salmerón J
Mol Carcinog; 2012 Aug; 51(8):608-18. PubMed ID: 21809392
[TBL] [Abstract][Full Text] [Related]
12. MT1 and MT2 melatonin receptors play opposite roles in brain cancer progression.
Kinker GS; Ostrowski LH; Ribeiro PAC; Chanoch R; Muxel SM; Tirosh I; Spadoni G; Rivara S; Martins VR; Santos TG; Markus RP; Fernandes PACM
J Mol Med (Berl); 2021 Feb; 99(2):289-301. PubMed ID: 33392634
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
14. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
Lee SH; Kim J; Kim WH; Lee YM
Oncogene; 2009 Jan; 28(2):184-94. PubMed ID: 18850007
[TBL] [Abstract][Full Text] [Related]
15. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
Liu Z; Marquez M; Nilsson S; Holmberg AR
Oncol Rep; 2008 Jul; 20(1):151-4. PubMed ID: 18575731
[TBL] [Abstract][Full Text] [Related]
16. Rhythmic expression of functional MT1 melatonin receptors in the rat adrenal gland.
Richter HG; Torres-Farfan C; Garcia-Sesnich J; Abarzua-Catalan L; Henriquez MG; Alvarez-Felmer M; Gaete F; Rehren GE; Seron-Ferre M
Endocrinology; 2008 Mar; 149(3):995-1003. PubMed ID: 18039783
[TBL] [Abstract][Full Text] [Related]
17. Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
Liang Y; Zeng J; Jelicks L; Ma S; Liu J; Mei J; Perez-Soler R; Zou Y
Curr Cancer Drug Targets; 2017; 17(2):169-176. PubMed ID: 27029827
[TBL] [Abstract][Full Text] [Related]
18. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
Zhang Y; Fatima N; Dufau ML
Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic mechanisms of melatonin action in human SH-SY5Y neuroblastoma cells.
Pan Y; Niles LP
Mol Cell Endocrinol; 2015 Feb; 402():57-63. PubMed ID: 25578604
[TBL] [Abstract][Full Text] [Related]
20. Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.
Zhang YW; Staal B; Dykema KJ; Furge KA; Vande Woude GF
PLoS One; 2012; 7(6):e38955. PubMed ID: 22701735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
